

# hRIF (D-14): sc-74662

## BACKGROUND

Human RING finger homologous to inhibitor of apoptosis protein (hRFI), also known as E3 ubiquitin-protein ligase RNF34, RING finger protein 34, or caspase-8 and -10 associated RING finger protein 1 (CARP-1), is a 372 amino acid apoptosis regulator protein. Expressed ubiquitously, hRFI has been observed at highest levels in testis, ovary, heart, skeletal muscle and esophageal carcinomas. hRFI has been shown to protect cells against apoptosis induced by TNF and 5-FU, and it also interacts with caspase-8 and caspase-10 to target them for proteasomal degradation. hRFI is auto-ubiquitinated and is proteolytically cleaved by caspases upon induction of apoptosis by TNF. These known functions of hRFI have identified it as a therapeutic target for gene therapy in various cancers.

## REFERENCES

1. Sasaki, S., Nakamura, T., Arakawa, H., Mori, M., Watanabe, T., Nagawa, H. and Croce, C.M. 2002. Isolation and characterization of a novel gene, hRFI, preferentially expressed in esophageal cancer. *Oncogene* 21: 5024-5030.
2. Sasaki, S., Watanabe, T., Konishi, T. and Nagawa, H. 2003. Expression of hRFI in digestive system cancer. *Nippon Rinsho* 61: 242-246.
3. Online Mendelian Inheritance in Man, OMIM™. 2003. Johns Hopkins University, Baltimore, MD. MIM Number: 608299. World Wide Web URL: <http://www.ncbi.nlm.nih.gov/omim/>
4. Sasaki, S., Watanabe, T., Konishi, T., Kitayama, J. and Nagawa, H. 2004. Effects of expression of hRFI on adenoma formation and tumor progression in colorectal adenoma-carcinoma sequence. *J. Exp. Clin. Cancer Res.* 23: 507-512.
5. Konishi, T., Sasaki, S., Watanabe, T., Kitayama, J. and Nagawa, H. 2005. Exogenous expression of hRFI induces multidrug resistance through escape from apoptosis in colorectal cancer cells. *Anticancer Res.* 25: 2737-2741.
6. Sasaki, S., Watanabe, T., Kobunai, T., Konishi, T., Kitayama, J. and Nagawa, H. 2005. High hRFI expression correlates with resistance to fluoropyrimidines in human colon cancer cell lines and in xenografts. *J. Exp. Clin. Cancer Res.* 24: 397-403.
7. Konishi, T., Sasaki, S., Watanabe, T., Kitayama, J. and Nagawa, H. 2005. Overexpression of hRFI (human ring finger homologous to inhibitor of apoptosis protein type) inhibits death receptor-mediated apoptosis in colorectal cancer cells. *Mol. Cancer Ther.* 4: 743-750.
8. Konishi, T., Sasaki, S., Watanabe, T., Kitayama, J. and Nagawa, H. 2006. Overexpression of hRFI inhibits 5-fluorouracil-induced apoptosis in colorectal cancer cells via activation of NFκB and upregulation of Bcl-2 and Bcl-X<sub>L</sub>. *Oncogene* 25: 3160-3169.
9. Sasaki, S., Watanabe, T., Kobunai, T., Konishi, T., Nagase, H., Sugimoto, Y., Oka, T. and Nagawa, H. 2006. hRFI overexpressed in HCT116 cells modulates Bcl-2 family proteins when treated with 5-fluorouracil. *Oncol. Rep.* 15: 1293-1298.

## CHROMOSOMAL LOCATION

Genetic locus: RNF34 (human) mapping to 12q24.31; Rnf34 (mouse) mapping to 5 F.

## SOURCE

hRIF (D-14) is an affinity purified goat polyclonal antibody raised against a peptide mapping within an internal region of hRIF of human origin.

## PRODUCT

Each vial contains 200 µg IgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

Blocking peptide available for competition studies, sc-74662 P, (100 µg peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA).

## APPLICATIONS

hRIF (D-14) is recommended for detection of hRIF of mouse, rat and human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

Suitable for use as control antibody for hRIF siRNA (h): sc-75301, hRIF siRNA (m): sc-75302, hRIF shRNA Plasmid (h): sc-75301-SH, hRIF shRNA Plasmid (m): sc-75302-SH, hRIF shRNA (h) Lentiviral Particles: sc-75301-V and hRIF shRNA (m) Lentiviral Particles: sc-75302-V.

Molecular Weight of hRIF: 42 kDa.

## RECOMMENDED SECONDARY REAGENTS

To ensure optimal results, the following support (secondary) reagents are recommended: 1) Western Blotting: use donkey anti-goat IgG-HRP: sc-2020 (dilution range: 1:2000-1:100,000) or Cruz Marker™ compatible donkey anti-goat IgG-HRP: sc-2033 (dilution range: 1:2000-1:5000), Cruz Marker™ Molecular Weight Standards: sc-2035, TBS Blotto A Blocking Reagent: sc-2333 and Western Blotting Luminol Reagent: sc-2048. 2) Immunofluorescence: use donkey anti-goat IgG-FITC: sc-2024 (dilution range: 1:100-1:400) or donkey anti-goat IgG-TR: sc-2783 (dilution range: 1:100-1:400) with UltraCruz™ Mounting Medium: sc-24941.

## STORAGE

Store at 4° C, \*\*DO NOT FREEZE\*\*. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

## RESEARCH USE

For research use only, not for use in diagnostic procedures.

## PROTOCOLS

See our web site at [www.scbt.com](http://www.scbt.com) or our catalog for detailed protocols and support products.